{"name":"Impax Laboratories, LLC","slug":"impax-laboratories-llc","ticker":"","exchange":"","domain":"impaxlabs.com","description":"","hq":"Hayward","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"oncology","drugs":[{"name":"CD-LD IR","genericName":"CD-LD IR","slug":"cd-ld-ir","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"phase_2"},{"name":"IPX066","genericName":"IPX066","slug":"ipx066","indication":"Parkinson's disease with motor fluctuations","status":"phase_3"},{"name":"Baclofen IR","genericName":"Baclofen IR","slug":"baclofen-ir","indication":"Spasticity associated with multiple sclerosis","status":"phase_2"},{"name":"CD-LD CR","genericName":"CD-LD CR","slug":"cd-ld-cr","indication":"Attention Deficit Hyperactivity Disorder (ADHD)","status":"phase_2"},{"name":"CLE","genericName":"CLE","slug":"cle","indication":"Parkinson's disease","status":"marketed"},{"name":"IPX203 ER CD-LD","genericName":"IPX203 ER CD-LD","slug":"ipx203-er-cd-ld","indication":"Parkinson's disease motor symptoms","status":"phase_3"},{"name":"IR CD-LD","genericName":"IR CD-LD","slug":"ir-cd-ld","indication":"Parkinson's disease motor symptoms","status":"phase_3"},{"name":"Placebo ZNS","genericName":"Placebo ZNS","slug":"placebo-zns","indication":"Adjunctive therapy for partial seizures in epilepsy","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Carbidopa capsule","genericName":"Carbidopa capsule","slug":"carbidopa-capsule","indication":"Other","status":"phase_1"},{"name":"IPX159","genericName":"IPX159","slug":"ipx159","indication":"Other","status":"phase_2"},{"name":"Moxifloxacin Tablets, USP","genericName":"Moxifloxacin Tablets, USP","slug":"moxifloxacin-tablets-usp","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CREXONT ER","genericName":"CREXONT ER","slug":"crexont-er","indication":"Bacterial infections caused by susceptible organisms (respiratory tract infections, skin and soft tissue infections, urinary tract infections)","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"IPX203","genericName":"IPX203","slug":"ipx203","indication":"Moderate to severe chronic pain requiring around-the-clock opioid therapy","status":"phase_3"}]}],"pipeline":[{"name":"CD-LD IR","genericName":"CD-LD IR","slug":"cd-ld-ir","phase":"phase_2","mechanism":"CD-LD IR is a central nervous system stimulant used to treat attention deficit hyperactivity disorder (ADHD).","indications":["Attention deficit hyperactivity disorder (ADHD)"],"catalyst":""},{"name":"IPX066","genericName":"IPX066","slug":"ipx066","phase":"phase_3","mechanism":"IPX066 is an extended-release formulation of levodopa and carbidopa designed to provide more consistent dopamine replacement in the brain over an extended period.","indications":["Parkinson's disease with motor fluctuations"],"catalyst":""},{"name":"Baclofen IR","genericName":"Baclofen IR","slug":"baclofen-ir","phase":"phase_2","mechanism":"Baclofen IR is a central nervous system depressant that acts as a GABA_B receptor agonist.","indications":["Spasticity associated with multiple sclerosis","Spasticity associated with spinal cord injuries"],"catalyst":""},{"name":"CD-LD CR","genericName":"CD-LD CR","slug":"cd-ld-cr","phase":"phase_2","mechanism":"CD-LD CR is a controlled-release formulation of a central nervous system stimulant.","indications":["Attention Deficit Hyperactivity Disorder (ADHD)"],"catalyst":""},{"name":"CLE","genericName":"CLE","slug":"cle","phase":"marketed","mechanism":"CLE is a combination formulation of carbidopa and levodopa in an extended-release delivery system designed to provide more consistent dopamine replacement in the brain for Parkinson's disease management.","indications":["Parkinson's disease"],"catalyst":""},{"name":"CREXONT ER","genericName":"CREXONT ER","slug":"crexont-er","phase":"marketed","mechanism":"CREXONT ER is an extended-release formulation of cephalexin, a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","indications":["Bacterial infections caused by susceptible organisms (respiratory tract infections, skin and soft tissue infections, urinary tract infections)"],"catalyst":""},{"name":"Carbidopa capsule","genericName":"Carbidopa capsule","slug":"carbidopa-capsule","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IPX159","genericName":"IPX159","slug":"ipx159","phase":"phase_2","mechanism":"Extended-release formulation of carbidopa-levodopa that provides sustained dopamine replacement in the brain for Parkinson's disease treatment.","indications":[],"catalyst":""},{"name":"IPX203","genericName":"IPX203","slug":"ipx203","phase":"phase_3","mechanism":"IPX203 is an extended-release combination of morphine and naltrexone designed to provide opioid analgesia while reducing the potential for abuse and addiction.","indications":["Moderate to severe chronic pain requiring around-the-clock opioid therapy"],"catalyst":""},{"name":"IPX203 ER CD-LD","genericName":"IPX203 ER CD-LD","slug":"ipx203-er-cd-ld","phase":"phase_3","mechanism":"IPX203 ER CD-LD is a combination extended-release formulation of carbidopa and levodopa designed to provide sustained dopaminergic replacement therapy for Parkinson's disease with reduced dosing frequency.","indications":["Parkinson's disease motor symptoms"],"catalyst":""},{"name":"IR CD-LD","genericName":"IR CD-LD","slug":"ir-cd-ld","phase":"phase_3","mechanism":"IR CD-LD is an immediate-release combination of carbidopa and levodopa designed to improve dopamine replacement therapy in Parkinson's disease with potentially faster onset and more consistent symptom control.","indications":["Parkinson's disease motor symptoms"],"catalyst":""},{"name":"Moxifloxacin Tablets, USP","genericName":"Moxifloxacin Tablets, USP","slug":"moxifloxacin-tablets-usp","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo ZNS","genericName":"Placebo ZNS","slug":"placebo-zns","phase":"phase_3","mechanism":"Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability through multiple mechanisms including sodium and calcium channel blockade.","indications":["Adjunctive therapy for partial seizures in epilepsy","Infantile spasms (West syndrome)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQLU9RU05YXzdYRG0yWUxqMWtleWVXenp4MmRWM0ZETVc0Q0YxWm8zVkUwOU9Cc0xORkdoOTIzZHN0VFM1VTV1dXNrRmFiOGY4UmNUclVBd3RqbjdfQ2d0dWF3eXY2dU96eVhXNTFieDcwbXM4d0tpWTNBSy1GMjhXMHdGWmxsRFV5RWJpbWUxWTlPZw?oc=5","date":"2022-09-01","type":"patent","source":"DCAT Value Chain Insights","summary":"Company Moves: The Latest in the Global Generics Market - DCAT Value Chain Insights","headline":"Company Moves: The Latest in the Global Generics Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxObGs3UXRRdDhBcTBaMV9ZNzgxRFpYTk01UkZqVmM3WFdjNXBpUkcwNHl5aEw4OTAxLXEwUklmTEw1d3c0cjBxMmJ2ejNLaXdmcWRJcWhvTkFZc0o1ZndpY1Vibkx4VXFETzY1TGx2T3RVSl9NbmFYNmUzWlMzRnc3aUs2VHd3dUtKdjA5dDEzRlVJUEFFTTcyRzlsSlhKYXU4MmZYdVdsWmlod3hL?oc=5","date":"2022-01-18","type":"patent","source":"The Business Journals","summary":"Vanda Pharmaceuticals settles with generic competitor - The Business Journals","headline":"Vanda Pharmaceuticals settles with generic competitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNcENXQjFmSk9NeTNEeS0yNU9wU0VZYnJZWmxTaVhKN0NpT1Roa1JnanFSUkdEQ2E2X00zaFZtN3dXai1qeXQ5Y1JTWGZnT0hsZjFZOVdUWGtTd3U4U2FTUDNaSnJXX2c1Z2tHdWp2SWd4TVB5cm13azlLN05PUUxGeVpiZG1qOVlDVjdHQzQyT3h6dnhMeEJsdlpaUEVhY3REY0JETDl0TkxhSVFQVVBFdV90bTVBZkRmUFlCNTNCaXB1TkM4WWlEWC00b1R0aG05WGJ3MUx0QjBxSlhXa25TQ0JnUkpfMUhzNndIYm9BTUo4Z1pVM1pVVTJ0bGk0ejBsS2FHclhtaHFHOENSVjVkWjFKckFKdlU?oc=5","date":"2021-04-18","type":"pipeline","source":"wsgr.com","summary":"Fifth Circuit Upholds Federal Trade Commission Ruling in Impax Laboratories, Inc. v. Federal Trade Commission and Grants Substantial Deference to the FTC - wsgr.com","headline":"Fifth Circuit Upholds Federal Trade Commission Ruling in Impax Laboratories, Inc. v. Federal Trade Commission and Grants","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOSm9qZmk3QVNXeHN2Ny03NXk0RWNZMVVJNkhJMGxFbEQ0d2x4cHJGcDNEd3k3cTNub0lnSzdXUmxFNWZ5THI5LUF2SkZVZ2JTd2lnTkxScTY2dkk2Y0J6dEEybUMtSnMwUkVDX1ZPNnhOazJKeUp6dy02MlpsdGY1a1UwYndVNE0tLXNucFFwWWNZRV8xMlhwbGpZNHhmMzQ?oc=5","date":"2020-06-02","type":"pipeline","source":"Allergic Living","summary":"Dosing Alert Issued on Some Impax, Amneal Auto-Injectors - Allergic Living","headline":"Dosing Alert Issued on Some Impax, Amneal Auto-Injectors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQTmwtc3gxT3FSaVNPQlNTcDdMWEo0cURjWDVzUE5PR0dVVGFTM1NqZVZhcmtLQUVRU3h6MURUOFU0ZUpUTzFNY2V0WUJTc3V5SV9yeVh5VHhhQkwzanNaaVc2bTBLR0tUaW5FVFMyYmIwaGZjQ2J2QnlyZXdCbFl6SklFWTlOMEZa?oc=5","date":"2018-08-08","type":"pipeline","source":"pharmacytimes.com","summary":"Amneal Pharmaceuticals - pharmacytimes.com","headline":"Amneal Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPTXE2dWhqRG00RnF2SkVCN25sZDUyOWloUHUzYkNxMVg4UUFhTzBMUUZRRWI5Nkl6LXR0bHZUTzFCOFhqTnoxeGo5dTRXVnoyaWtFXy1TWFQtSnBnMGFTdXpKaHRxbjgySURkWWxJMVlndlB1S0Ftamdjc3ZiQ29FckpB?oc=5","date":"2018-01-31","type":"deal","source":"New Jersey Business Magazine","summary":"CorePharma, LLC Acquired by Investor Group - New Jersey Business Magazine","headline":"CorePharma, LLC Acquired by Investor Group","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPVzRMampfLUFFaTU4dndVbEZiVGttOUgtWTlzazVVV0IxZ3JjUHBla0JsczF3UnZQcFUyUWNPQzdwVk1oZ193OGJCRjl2dnNEanFJZ09UWHRwVVJjZ0tPUFRMSjktQ2VxOHNXOFBySHRYWTBXMXhfemlINkV6U2xXOGVNOXd3WDJfbi1aZg?oc=5","date":"2017-10-17","type":"patent","source":"BioPharma Dive","summary":"Amneal, Impax combine amid generics crunch - BioPharma Dive","headline":"Amneal, Impax combine amid generics crunch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQcERwNTRWRllFaEc1THpuOHZEem5jaFplVVZpLU95ZFA0T3dSNXlqNmJwSVFWVTN5TTlRS1FxZWZWcmU4TU1CS1dlb1A5MHp6ZnF1bGQ0TkdSR2VRd2FDOWthOERFQW1adTIyLUItRldYbFBub2h6RHlrV00zY29TNVpWMGp4U2lrS3Zqa0RId0NPVjY0OGE3VXBFVWxYT1BIMWc?oc=5","date":"2017-10-17","type":"pipeline","source":"WSJ","summary":"Impax Laboratories and Amneal Pharmaceuticals Agree to Merge - WSJ","headline":"Impax Laboratories and Amneal Pharmaceuticals Agree to Merge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQWHk2SkdnOGpEeDdNNFltTzNYczZqa25VZ0JRamdwY3gwRkxHRmhQSFZVQTY1d2hOdWhWLVFEYjllQXJpVTBEM3oxVjM5OUFJMW9tbWI1d1IwanpvUVpyRXFCc3JZazFSc3lsOGl5aWREaVk4X0NHa1duSXRZaDBqRDVNdXFvazZYSnQw?oc=5","date":"2017-10-17","type":"pipeline","source":"prnewswire.com","summary":"Amneal And Impax To Combine - prnewswire.com","headline":"Amneal And Impax To Combine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPZVNkRVNoX0duVnpXejI0WmpuejQ4TUtlSDZEMS1faFFuMmgzRTdBWGFJa21QeDhUZ2xNamNNMnVqcktKLUhUMHZyQ2R5Q2tXYVEzTk5rQUt0a0NRQlZhbTdNSG1NVmN5Ujl1ZzRJaktULV94R2tWQ1lvWldULUdia0RTdldYamNxNDlHQ2k4R1F3Z0JkYVdBa045YncwWTdkbDNibUhtb25hNmJtZmRjb0Z2NVpBY09hYnc?oc=5","date":"2017-10-17","type":"deal","source":"Fierce Pharma","summary":"Bisaro steers Impax to $6.4B Amneal merger, creating fifth-largest U.S. generics company - Fierce Pharma","headline":"Bisaro steers Impax to $6.4B Amneal merger, creating fifth-largest U.S. generics company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQUUZvMlI0dzRlM2FlazNYb0szUUZJOHloYjBBRVRhdXZVSWJHV3BZVnRmZkdsVG5qUl9SVkNzT2oxWW9lQlhUOWVobF9qNTFrakZwN1lYdUtIdHN1NTNoMXBSZkgwRFR5RmtFSVU4VEtubEdnZ0RJazZpcGxMNng3ekdjM3ViaG9VLW0tOTZPSEduaUFlN09aUzlWWFdVb2JaYXdoN3o1dEMyM3M?oc=5","date":"2017-10-16","type":"deal","source":"WSJ","summary":"Impax Laboratories and Amneal Pharmaceuticals Near Merger Agreement - WSJ","headline":"Impax Laboratories and Amneal Pharmaceuticals Near Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5fLXMxOHJ6QWhTZkNQNW93SGpmVzl5UE9sZ2JRWUNnay1tamo3cVlYVFplUXAtajFNSDMtR0FTejNRNE5SVUNTNXdEcUlYOVM1aHVEV25ZQzNkRXRocWc?oc=5","date":"2016-08-26","type":"patent","source":"pharmacytimes.com","summary":"Impax Generics - pharmacytimes.com","headline":"Impax Generics","sentiment":"neutral"}],"patents":[],"drugCount":13,"phaseCounts":{"phase_2":4,"phase_3":5,"marketed":2,"phase_1":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}